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A B S T R A C T
Background: Ninety conﬁrmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have
been reported to the World Health Organization. We report the details of a second family cluster of
MERS-CoV infections from Riyadh, Saudi Arabia.
Methods: We present the clinical, laboratory and epidemiological details of 3 patients from a family
cluster of MERS-CoV infections.
Results: The ﬁrst patient developed respiratory symptoms and fever 14 days after admission to hospital
for an unrelated reason. He died 11 days later with multi-organ failure. Two of his brothers presented
later to another hospital with respiratory symptoms and fever. MERS-CoV infection in the latter 2
patients was conﬁrmed by reverse transcriptase polymerase chain reaction testing. All 3 patients had
fever, cough, shortness of breath, bilateral inﬁltrates on chest x-ray, thrombocytopenia, lymphopenia
and rises in serum creatinine kinase and alanine transaminase. No hospital or other social contacts are
known to have acquired the infection. It appears that the index patient in this cluster acquired MERS-CoV
infection whilst in hospital from an unrecognized mild or asymptomatic case.
Conclusion: MERS-CoV acquisition from unrecognized mild or asymptomatic cases may be a more
important contributor to ongoing transmission than previously appreciated.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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A novel coronavirus causing severe respiratory infection was
ﬁrst described in September 2012.1 The virus, which later became
known as Middle East Respiratory Syndrome Coronavirus (MERS-
CoV), belongs to lineage C of the genus Betacoronavirus and is
closely related to bat coronaviruses HKU4 and HKU5.2,3 Though an
animal reservoir is considered likely, none has been identiﬁed yet.4
The exact mechanism through which MERS-CoV infection is
acquired remains uncertain. Up to 24 July 2013, a total of 90
conﬁrmed cases of MERS-CoV infection have been reported to the* Corresponding author. Tel.: +9661-2124052; fax: +9661-2125052;
Mobile:+966-5-05483515.
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Nakhli), zmemish@yahoo.com (Z.A. Memish), draalbarrak@yahoo.com
(A.M. Albarrak).
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http://dx.doi.org/10.1016/j.ijid.2013.07.001World Health Organization (WHO), including 45 deaths. The
majority of infections are sporadic. Human to human transmission
has been documented in at least 3 hospital settings6–8 and 4
community clusters.9–12 We report the clinical and epidemiologi-
cal details of a second family cluster of two conﬁrmed and one
probable MERS-CoV infections in Riyadh, Saudi Arabia, occurred in
February and March 2013. We hypothesize that the index case in
the cluster is likely to have acquired the infection whilst in hospital
from a contact with unrecognized MERS-CoV infection.
2. Case histories
Patient 1 was a 51-year old male with history of obesity and
uncomplicated type II diabetes mellitus. He was admitted on 30
January 2013 thru the Emergency Department in Hospital A in
Riyadh, Saudi Arabia, with a 2-month history of progressive back
pain, lower limb weakness and urinary incontinence. There was no
history of travel or recent contact with sick animals. Magneticses. Published by Elsevier Ltd. All rights reserved.
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lumbar vertebral level. Further investigations conﬁrmed a
diagnosis of multiple myeloma. He was transferred to a medical
ward on 8 February 2013 for further management. On 13 February
2013, 14 days after hospital admission, he developed high fever,
cough, shortness of breath and hypoxia requiring high ﬂow oxygen
via face mask. He commenced meropenem, vancomycin, vorico-
nazole and oseltamivir. By the morning of 15 February 2013, his
condition deteriorated with respiratory failure and progressive
pulmonary inﬁltrates on chest x-ray. He was transferred to the
intensive care unit (ICU) where he was intubated and put on
mechanical ventilation. Renal failure ensued and continuous renal
replacement therapy was started on 18 February 2013. Colistin and
tigecycline were added on 20 February 2013. The patient’s
condition remained poor and he passed away on 24 February
2013, 11 days after the onset of his respiratory symptoms. Bacterial
cultures of blood, urine and sputum were all negative.
Patient 2, a 39-year old brother of Patient 1 and Patient 2,
became unwell on 24 February 2013 with fever, generalized
fatigue, cough productive of bloody sputum and progressive
shortness of breath. He had had no signiﬁcant past medical history
prior to this acute illness. He visited a private clinic on 27 February
2013 and was prescribed a course of oral cefuroxime without any
improvement. He was admitted on 28 February to Hospital B in
Riyadh, Saudi Arabia with hypoxia and extensive bilateral
pulmonary inﬁltrates (Figure 1). He received vancomycin, piper-
acillin-tazobactam, azithromycin and oseltamivir, in addition to
intravenous hydrocortisone and high ﬂow oxygen by a face mask.
Twenty-four hours later, he required endotracheal intubation and
mechanical ventilation. The next day, vancomycin and piperacil-
lin-tazobactam were substituted with linezolid and imipenem and
his ventilation was switched to high frequency oscillatory mode.
On 2 March 2013, continuing respiratory failure prompted a shift
to extra-corporal membrane oxygenation. The patient’s clinical
condition failed to improve and he passed away 2 hours later, 7
days after the onset of symptoms. Cultures of blood, urine and
sputum taken at the time of admission to hospital were all
negative. Candida albicans was isolated from culture of sputumFigure 1. Chest radiograph from patient 2 with severe MERS-CoV pneumonia
showing bilateral pulmonary inﬁltrates.taken on 2 March 2013. Sputum smear microscopy for acid-fast
bacilli and mycobacterial cultures were negative.
Patient 3, a 40-year old brother to patient 1 and 2, became ill on
2 March 2013. He was overweight but had no pre-existing chronic
medical illness. He was admitted to Hospital B on 4 March 2013
with fever and cough productive of clear sputum. His initial chest
x-ray was unremarkable. He received ceftriaxone, azithromycin
and oseltamivir. A chest x-ray, taken 3 days later, showed focal
areas of consolidation in the right middle and upper lobes. A
computerized axial tomographic scan of the chest showed
bilateral, peripheral air space consolidation with some degree
of ground glass changes (Figure 2). His clinical course remained
largely uncomplicated. He did not receive any corticosteroids,
immune modulatory therapy or antivirals other than oseltamivir.
Patient 3 was discharged from hospital alive and well on 11 March
2013. Cultures of respiratory tract samples, blood and urine were
all negative. Sputum smear microscopy for acid-fast bacilli and
mycobacterial cultures were also negative.
Key clinical ﬁndings for the 3 patients are summarized in
Table 1. Figure 3 illustrates the clinical course and timelines for the
3 patients.
3. Laboratory testing
Patient 1 had no samples tested for respiratory viruses or MERS-
CoV. Nasopharyngeal swabs from Patient 2 and Patient 3 and a
tracheal aspirate from Patient 2 were all negative by reverse
transcriptase polymerase chain reaction (RT-PCR) for Inﬂuenza A
virus RNA, Inﬂuenza B virus RNA, H1N1 Inﬂuenza virus RNA,
Respiratory syncytial virus RNA, Adenovirus DNA, Rhinovirus RNA
and seasonal Coronavirus RNA (HCoV 229, OC43, NL63). RT-PCR
testing for MERS-CoV upE, ORF 1b and N genes was positive on
upper and lower respiratory tract samples from Patient 2. Two
upper respiratory tract samples from Patient 3 were negative;
while a lower respiratory tract sample collected a day earlier was
positive for MERS-CoV. All RT-PCR tests for MERS-CoV were
performed at the Saudi Ministry of Health regional laboratory in
Jeddah, and conﬁrmed at the Public Health England, United
Kingdom, Laboratories.13,14
4. Contact investigation
All 3 patients lived in one large house in Urban Riyadh. There
were 10 adults in the household; the mother, who had history ofFigure 2. Computerized tomography scan from patient 3 with mild to moderate
MERS-CoV infection showing bilateral peripheral air space consolidation.
Table 1
Clinical and investigational features of a family cluster of 3 patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections from Riyadh, Saudi Arabia
and from previously reported cases.a
Patient 1 Patient 2 Patient 3 Data from previous MERS-CoV reportsb
Fever Yes Yes Yes 30/33 (90.9%)
Cough Yes Yes Yes 30/33 (90.9%)
Dyspnea Yes Yes Yes 20/33 (60.6%)
Gastrointestinal symptoms No No No 12/33 (36.4%)
Chest x-ray inﬁltrates Yes Yes Yes 25/33 (75.8%)
Lymphopenia Yes Yes Yes 9/9 (100%)
Thrombocytopenia Yes Yes Yes 11/32 (34.4%)
Creatinine kinase rise Yes Yes Yes 2/2 (100%)
Alanine transaminase rise Yes Yes Yes 3/7 (42.9%)
Lactate dehydrogenase rise Not available Yes Yes 3/6 (50%)
Acute renal failure Yes Yes No 7/10 (70%)
ICUc admission Yes Yes No 26/33 (78.8%)
Mechanical ventilation Yes Yes No 26/33 (78.8%)
a Data collated from reports in which clinical details of patients with MERS-CoV infection were made available.1,7,8,10,19,24,27
b Numerator indicates number of patients in whom a particular characteristic was present; denominator indicates the total number in which the presence or absence of the
particular characteristic was reported.
c ICU denotes intensive care unit.
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sion, bronchial asthma and hypothyroidism, Patient 1 and his wife,
4 others sons (including Patient 2 and Patient 3), 2 daughters, and a
female housemaid. Moreover, 4 married daughters and their
spouses and children visited the family home frequently and often
slept over too. The married couple shared one bedroom. Each of the
other members of the household had his or her own bedroom. The
men and women usually had their meals separately. Patients 2 and
3 are described as very close, spending most of their free time
together. There were no domestic animals or birds in the family
home, but bats had been noted in a small neglected park behind the
house. Patient 1 had a farm outside Riyadh, in which he kept sheep,
chicken, ducks and pigeons. He visited the farm once or twice a
week. His last visit was 2 days prior to his admission to hospital.
Patient 2 visited the farm occasionally. He also climbed palm treesFigure 3. Clinical timelines for three patients with deﬁnite or probable Min the house garden from time to time to pollinate the dates. None
of the other family members frequented Patient 1’s farm.
Patient 1 was initially admitted to a curtained-off bed in the
Emergency Department where he stayed for 9 days. He was then
transferred to a 2-bedded room in a medical ward where he stayed
for 2 nights. A comatose patient, who had no visitors, occupied the
second bed in the room. Patient 1 was moved once more to another
2-bedded room in the same ward. His roommate was discharged
home 2 days later and the bed remained unoccupied for the
remainder of the time that Patient 1 was in the room. Patient 2 and
Patient 3 visited Patient 1 in the ward and in the ICU several time
but usually did not stay for too long. Numerous friends, relatives
and work colleagues visited Patient 1 while he was in the ward,
before developing fever and respiratory symptoms. Patient 1’s wife
and 2 of his unaffected brothers spent especially long periods ofiddle East Respiratory Syndrome Coronavirus (MERS-CoV) infection.
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and medical care for Patient 1 followed standard infection control
precautions.
Inﬂuenza was suspected upon Patient 2’s admission to Hospital
B. He was transferred to a single room within 2 hours of his arrival
and healthcare staff implemented contact and droplet infection
control precautions throughout the patient’s hospital stay.15 The
patient’s visitors were directed to do the same. On clinical
deterioration, Patient 2 was transferred to the Resuscitation Bay
in the main Emergency Department, where he was intubated in the
presence of 5 healthcare workers (HCWs), all of whom wore
surgical masks, gloves and full-length isolation gowns. Patient 2
was later transferred to a single room in the ICU, where droplet and
contact precautions continued.
MERS-CoV infection was suspected upon Patient 3’s presenta-
tion. He was thus admitted directly into a single room where all
care was provided under strict contact and droplet infection
control precautions.15
Nasopharyngeal swabs obtained from all household contacts of
the patients were negative by RT-PCR for MERS-CoV infection.
Moreover, all household contacts were followed daily for 14 days
for presence of respiratory symptoms and none developed any.
Serum samples were also obtained and stored pending the
availability of validated serological assays. In the ensuing weeks,
no HCWs in either hospital developed any symptoms to fulﬁll the
surveillance requirement for MER-CoV testing.16 Patient 2 was
overtly symptomatic during Patient 1’s funeral. None of the dozens
of mourners who attended the funeral is known to have developed
a respiratory illness consistent with MERS-CoV infection.
5. Discussion
Patient 1’s clinical course and subsequent microbiological
conﬁrmation of MERS-CoV infection in his brothers provide
adequate basis for labeling his illness as probable MERS-CoV
infection.17 The onset of his symptoms was 14 days after admission
to hospital. He had spent 9 days in the Emergency Department
before he was transferred to 2 different 2-bedded rooms. The upper
end of MERS-CoV incubation period is thought to be around 14
days, with most patients having symptoms within the ﬁrst week of
contact.8,18 It is therefore likely that Patient 1 acquired MERS-CoV
infection during his hospitalization. This could have been from an
asymptomatic HCW, one of the patients who were placed in close
proximity to Patient 1 during his stay in the Emergency
Department or from one of the numerous visitors he received
whilst in the medical ward. In a previously described family cluster
of MER-CoV infections, the index patient had a protracted clinical
course including urinary tract infection and cardiac failure before
respiratory infection became apparent.10 The authors suggest that
in-hospital acquisition might be one explanation. Furthermore, in
the largest human-to-human cluster of MERS-CoV infections
described so far, one of the index cases was identiﬁed as a
probable case based on his son’s subsequent positive test.8
Unrecognized MERS-CoV infection in the community and in
healthcare settings may be a more signiﬁcant problem than
previously appreciated.
The two family contacts of Patient 1 who went on to develop
MERS-CoV infection had substantially less direct contact with him
than other family members. It was suggested that higher viral
shedding during the earlier phase of the clinical illness may result
in higher infectiousness.19 In our report however, Patient 1’s wife
and two of his unaffected brothers were in regular close contact
with him throughout his illness without ever taking any speciﬁc
infection prevention precautions. They, as well as numerous other
social and healthcare contacts, remained well. It continues to beunclear why some close contacts of individuals with MERS-CoV
infection develop a clinical illness while others do not.
A large number of HCWs were in close contact with Patient 1
and Patient 2, some of which did not adhere strictly to appropriate
infection control precautions. None of them was apparently
infected. This is not dissimilar to the observations from four
previous extensive public health investigations into cases of MERS-
CoV infections. Out of over 400 HCWs who had been in contact
with 31 patients in 4 different countries, only 2 had documented
MERV-CoV infection.8,9,20,21 Whether HCWs play a role in
transmitting MERS-CoV through hand and surface contamination
is an interesting but yet unproven hypothesis. Fourteen conﬁrmed
cases of asymptomatic MERS-CoV infection have so far been
reported to the WHO, including 4 HCWs.22 Such asymptomatic
carriage may explain some of the transmission that has taken place
in hospital and in community settings. Furthermore, phylogenetic
analyses of the available MERS-CoV genomes suggested a common
ancestor halfway through the year 2011.8,19 It appears that the
virus circulated in the community for at least one year before the
ﬁrst clinical case was recognized.
The relatively low attack rate amongst social and HCW contacts
in our report and in previous reports is reassuring but should not
detract from continuing aggressive efforts to understand the
pathogenesis of MERS-CoV. Two recent documented outbreaks
illustrate the possible risks. Human to human transmission in 3
hospitals in eastern Saudi Arabia was responsible for 21 out of 23
MERS-CoV infections, of which at least 15 were fatal.8 Another
outbreak in Jordan in April 2012 affected a total of 13 individuals,
including 10 HCW.6,23
The recommended contact and droplet precautions were
implemented to a reasonable extent during the hospital care for
all patients in our report.15 Reassuringly, this appears to have been
effective in preventing nosocomial transmission of MERS-CoV.
Previous studies showed that from the onset of illness, MERS-CoV
was detectable by RT-PCR up to 14 days in lower airway samples,
13 days in urine and 16 days in stool.7,19,24 The importance of
stringent infection control practice to interrupt any potential
sustained MERS-CoV transmission can not be over stated.
MERS-CoV infection was fatal in 2 of the 3 patients described in
our report. The high mortality rate associated with MERS-CoV
infection increasingly appears to be due to the under-diagnosis of
mild and asymptomatic cases as a result of the restrictive case
deﬁnition put forward by WHO.16 All 3 patients in our report had
fever, cough, shortness of breath, pulmonary inﬁltrates on chest x-
rays, lymphopenia, thrombocytopenia and rises in serum creati-
nine kinase and alanine transaminase. All these are relatively
common clinical features amongst patients with MERS-CoV
infection (Table 1). Many of these were also seen in patients
affected by Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV) outbreak in 2003; however, the 2 diseases have
distinctly different infectivity patterns.25 Although not necessarily
diagnostic, the presence of these ﬁndings without an alternative
explanation should prompt earlier consideration of MERS-CoV
infection and initiation of appropriate investigations. It should be
noted that collating data from small reports in order to understand
the clinical features of an emergent infection has numerous self-
evident limitations. A global, collaborative effort among clinicians
and scientists studying this disease is needed to develop and
identify more predictive diagnostic and prognostic markers.26
A number of knowledge gaps remain in relation to MERS-CoV
infection. These include identiﬁcation of its source and intermedi-
ate host and better understanding of the pathogenesis, infectivity
and risk factors. Further work is also needed to optimize MERS-CoV
diagnostic assays and to identify the most effective therapeutic
interventions. The existing number of cases globally over the past 2
years is relatively small to address all these areas.
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In-hospital transmission of MERS-CoV infection from unde-
tected infection or asymptomatic carriage may be a larger
contributor than previously appreciated. Early recognition of
MERS-CoV infected patients and rigorous implementation of
appropriate infection control measures are essential for effective
control of the epidemic.
Conﬂict of interest statement: All authors have no ﬁnancial or
personal relationships with other people or organizations that
could inappropriately inﬂuence this report. No funding was
received from any source for this work.
References
1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation
of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med
2012;367:1814–20.
2. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al.
Genomic characterization of a newly discovered coronavirus associated with
acute respiratory distress syndrome in humans. mBio 2012;3. http://dx.doi.org/
10.1128/mBio.-12. pii: e00473-12.
3. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Middle
East Respiratory Syndrome Coronavirus (MERS-CoV); Announcement of the
Coronavirus Study Group. J Virol 2013;87:7790–2.
4. World Health Organization. WHO guidelines for investigation of cases of human
infection with Middle East Respiratory Syndrome Coronavirus (July 2013).
(Accessed 12 July 2013, at http://www.who.int/csr/disease/coronavirus_infec-
tions/MERS_CoV_investigation_guideline_Jul13.pdf).
6. Hijawi B, Abdallat M, Sayaydeh A, et al. Novel coronavirus infections in Jordan,
April 2012: epidemiological ﬁndings from a retrospective investigation. East
Mediterr Health J 2013;19:S12–8.
7. Guery B, Poissy J, El Mansouf L, Sejourne C, Ettahar N, Lemaire X, et al. Clinical
features and viral diagnosis of two cases of infection with Middle East Respira-
tory Syndrome Coronavirus: a report of nosocomial transmission. Lancet
2013;381:2265–72.
8. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DAT, et al.
Hospital outbreak of Middle East Respiratory Syndrome Coronavirus. N Engl J
Med 2013. http://dx.doi.org/10.1056/NEJMoa1306742.
9. Health Protection Agency UKNCIt. Evidence of person-to-person transmission
within a family cluster of novel coronavirus infections, United Kingdom,
February 2013. Euro Surveill 2013;18. pii: 20427.
10. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family
cluster of Middle East Respiratory Syndrome Coronavirus infections. N Engl J
Med 2013;368:2487–94.
11. World Health Organization. MERS-CoV summary and literature update - 31
May 2013.(Accessed 12 July 2013, at http://www.who.int/csr/disease/corona-
virus_infections/update_20130531/en/index.html.).12. World Health Organization. Update: Middle East respiratory syndrome coro-
navirus (MERS-CoV) - 2 June 2013.(Accessed 12 July 2013, at http://
www.who.int/csr/don/2013_06_02_ncov/en/index.html.).
13. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al.
Detection of a novel human coronavirus by real-time reverse-transcription
polymerase chain reaction. Euro Surveill 2012;17. pii: 20285.
14. Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for
laboratory conﬁrmation of novel human coronavirus (hCoV-EMC) infections.
Euro Surveill 2012;17. pii: 20334.
15. World Health Organization. Infection prevention and control of epidemic- and
pandemic-prone acute respiratory diseases in health care - WHO Interim
Guidelines June 2007.(Accessed 12 July 2013, at http://apps.who.int/iris/bit-
stream/10665/69707/1/WHO_CDS_EPR_2007.6_eng.pdf.).
16. World Health Organization. Interim surveillance recommendations for human
infection with novel coronavirus - 3 December 2012.(Accessed 12 July 2013, at
http://www.who.int/csr/disease/coronavirus_infections/InterimRevisedSur-
veillanceRecommendations_nCoVinfection_03Dec12.pdf.).
17. World Health Organization. Revised interim case deﬁnition for reporting to WHO
– Middle East respiratory syndrome coronavirus (MERS-CoV) - Interim case
deﬁnition as of 03 July 2013.(Accessed 12 July 2013, at http://www.who.int/
csr/disease/coronavirus_infections/case_deﬁnition/en/index.html.).
18. Centers for Disease Control and Prevention. Update: Severe respiratory illness
associated with Middle East Respiratory Syndrome Coronavirus - worldwide,
2012–2013. MMWR Morb Mortal Wkly Rep 2013;62:480–3.
19. Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, et al.
Clinical features and virological analysis of a case of Middle East respiratory
syndrome coronavirus infection. Lancet Infect Dis 2013. http://dx.doi.org/
10.1016/S473-3099(13)70154-3.
20. Buchholz U, Muller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, et al.
Contact investigation of a case of human novel coronavirus infection treated in
a German hospital, October-November 2012. Euro Surveill 2013;18. pii: 20406.
21. Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, et al. First cases
of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in
France, investigations and implications for the prevention of human-to-human
transmission, France, May 2013. Euro Surveill 2013;18. pii: 20502.
22. World Health Organization. MERS-CoV summary and literature update as of 09
July 2013.(Accessed 12 July 2013, at http://www.who.int/csr/disease/corona-
virus_infections/update_20130709/en/index.html.).
23. World Health Organization. Novel coronavirus summary and literature update
as of 25 April 2013.(Accessed 12 July 2013, at http://www.who.int/csr/disease/
coronavirus_infections/update_20130425/en/index.html.).
24. Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, et al. Severe
respiratory illness caused by a novel coronavirus, in a patient transferred to the
United Kingdom from the Middle East, September 2012. Euro Surveill 2012;17.
pii: 20290.
25. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of
severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–
94.
26. Cauchemez S, Van Kerkhove M, Riley S, Donnelly C, Fraser C, Ferguson N.
Transmission scenarios for Middle East Respiratory Syndrome Coronavirus
(MERS-CoV) and how to tell them apart. Euro Surveill 2013;18. pii: 20503.
27. Albarrak AM, Stephens GM, Hewson R, Memish ZA. Recovery from severe novel
coronavirus infection. Saudi Med J 2012;33:1265–9.
